&w=3840&q=100)
Only one person on Earth has this blood type. What is 'Gwada negative'?
'Gwada negative' has been established as the 48th blood group system in the world. Representational Image/AI-generated via Firstpost
A woman from the French Caribbean territory of Guadeloupe has been confirmed as the only known person in the world to possess a newly classified blood group — now officially recognised as the 48th blood group system.
The new blood group has been named 'Gwada negative', after a local nickname for the islands of Guadeloupe.
The discovery was announced by France's national blood service, Établissement français du sang (EFS), following its formal recognition by the International Society of Blood Transfusion (ISBT) at its congress in Milan.
STORY CONTINUES BELOW THIS AD
The ISBT had previously identified 47 unique blood group systems. This development comes more than a century after Austrian-American biologist Karl Landsteiner first identified the ABO system in 1901, a milestone that would later earn him a Nobel Prize.
How 'Gwada negative' was discovered
The woman in question, now 68 years old and living in Paris, first drew the attention of medical researchers in 2011. At the time, she was undergoing routine pre-surgical blood tests.
Initial laboratory tests failed to classify her blood using any known blood typing methods. An atypical antibody was identified, and her blood could not be matched within existing systems.
A 'very unusual' antibody was first found in the patient in 2011, Thierry Peyrard, a medical biologist from EFS, who has played a key role in the study, told AFP.
However, at the time of the initial tests, the tools and technology available were insufficient to explore the anomaly further.
The case remained unexplained for nearly eight years, until 2019, when scientists at EFS returned to her sample using a more advanced diagnostic tool — high-throughput DNA sequencing.
This technology enabled researchers to conduct a deeper genetic investigation, ultimately revealing a mutation in the PIGZ gene, which alters how specific proteins anchor themselves to red blood cells.
The woman was confirmed to have inherited the condition from both her parents, who each carried a version of the mutated gene. This made her the only known person on Earth to have this specific blood group.
STORY CONTINUES BELOW THIS AD
'She is the only person in the world who is compatible with herself,' said Peyrard.
He noted that the name 'Gwada negative' was chosen in reference to the patient's Guadeloupean origin and also because 'it sounds good in all languages,' making it a suitable term for global usage among the scientific and medical communities.
What makes blood types so complex
Though most people know their blood type as A, B, AB, or O — combined with a positive or negative Rh factor — these are just the best-known components of a vast and intricate system.
Human red blood cells carry more than 600 different antigens, and each unique combination of these can result in a new blood type.
For this reason, the ISBT recognises blood group systems rather than individual blood types. Each system is defined by the genetic and serological properties that influence the expression of antigens.
The ABO and Rh systems are the most clinically important, especially for transfusions, but over the years, dozens of others have been identified, including rare ones that affect transfusion compatibility and immune response.
The addition of Gwada negative follows previous rare group discoveries such as the 'Er' system, which was recognised in 2022.
STORY CONTINUES BELOW THIS AD
Scientific progress in gene sequencing, particularly high-throughput genomic tools, has accelerated the pace of discovery in recent years. According to experts, more new blood groups may be identified annually as sequencing technologies become more widespread and affordable.
What this means for rare blood group carriers
Understanding blood types is critical in transfusion medicine. When blood from a donor carries antigens that are not recognised by the recipient's immune system, it can trigger a dangerous immune reaction, which can be life-threatening.
The ABO-Rh system offers transfusion compatibility in 99.8 per cent of cases, but patients with rarer blood types face greater risk and more limited donor options.
The EFS highlighted this point in its public statement: 'Discovering new blood groups means offering patients with rare blood types a better level of care.'
Although millions of theoretical blood types are possible based on antigen variation, only 48 blood group systems have met the rigorous genetic and serological criteria to be recognised by the ISBT.
Every addition to this list not only advances the scientific understanding of human genetics but also enhances the safety and efficacy of transfusions for rare cases.
In the United States alone, the Centers for Disease Control and Prevention (CDC) reports that more than 14 million units of blood are transfused annually. Accurate typing and identification are essential to ensure those transfusions are both safe and effective.
STORY CONTINUES BELOW THIS AD
Why this puts the woman with 'Gwada negative' in a unique position
The woman with Gwada negative blood is unique in more ways than one.
Unlike other rare blood types that may have small numbers of known carriers, she is the only confirmed person worldwide with this classification, making her completely incompatible with any blood donor currently known to science — except herself.
This reality poses major challenges should she ever require a transfusion. Her genome sequencing has been archived, and researchers are now focused on locating other potential carriers, particularly among blood donors from Guadeloupe and surrounding regions.
Because blood types are inherited, populations with shared ancestry may be the most likely sources of other cases.
The blood group's formal recognition by the ISBT not only gives it a place in global transfusion protocols, but also encourages international collaboration to identify other carriers and develop strategies for rare donor recruitment.
With inputs from agencies
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
4 hours ago
- Indian Express
‘I had the American dream, but I dropped it': 4 family members share the unseen toll of cancer caregiving in India
Sakshi Agrawal had just finished school – her life was only beginning– when tragedy struck: her father was diagnosed with oral cancer. At 18, she made a decision that would define the next two years – she paused her education to care for him. 'I stayed home to manage his treatment and care. It wasn't just about missing college—it was about putting my entire life on hold,' recallsed Agrawal, now 31. Her brother eventually quit his job and returned home during their father's final months, sacrificing career opportunities in a field with limited prospects locally. Agrawal's story isn't unique. Across India, millions quietly shoulder the exhausting responsibility of caring for loved ones with cancer, often becoming invisible casualties of a disease that demands everything from everyone it touches. In India, where family obligation runs deep, caregiving is rarely seen as a choice; it's an expectation. But the emotional and physical toll this takes on families remains largely unspoken, hidden behind cultural notions of duty and sacrifice. 'I associate one word with caregiving: exhaustion. Bone-crushing exhaustion,' said Saumya Sharma, 31, who cared for her father from 2018 until he passed in 2021, and is now supporting her mother through breast cancer treatment. 'The other one is probably resentment. Resentment with the sick, maybe sometimes, but mostly it is resentment with the situation. No matter what you do as a caregiver, it is never enough. It is as if you stop existing and now only the sick person exists,' she told A 2022 study cited by mental health expert Anjali Pillai, psychologist and programmes lead at SafeStories, Pune, found that two in five caregivers of cancer patients screened positive for depression. Yet, she says, this is just the tip of a crisis hiding in plain sight. For Pavithra Sekar, 28, caring for her mother with stage 3 breast cancer means living in a constant state of vigilance. 'Your brain always has the guard switch on. My mom won't sleep easily, and often she won't say what's bothering her, and we end up in the ER. There are no peaceful nights.' The financial burden is crushing. 'Cancer is a chronic disease, so not all bills are covered by insurance. Surgery and radiation are covered, but chemotherapy and regular medication are not. Medicine alone costs us Rs 20,000 a month,' she said. To manage expenses, Sekar lives on the city's outskirts, enduring a six-hour daily commute to work. The personal toll is just as devastating. 'I've been turned down by men and their families because they fear I'll also get cancer and they won't be able to support us,' she said, adding, 'No one really understands the intensity of cancer.' Sharma's sacrifice was perhaps the most dramatic. After earning admission to an Ivy League MBA programme and working in Boston, she returned to India in 2021 when her father's health declined. 'My company was applying for my H1B, but I dropped the American dream. I don't regret it. I was restless in the US knowing my family was suffering.' Healthcare professionals are witnessing this crisis firsthand. Dr Srinath, senior oncologist and founder at Asha Hospitals, observed that 'caregivers often carry the emotional weight of the diagnosis as heavily as the patient, but with far fewer outlets to express it.' The impact on patient care is direct and measurable. 'When a caregiver's physical or emotional reserves are depleted, it affects their ability to provide consistent and compassionate care. I have seen instances where caregiver exhaustion compromises the accuracy of medication administration or leads to missed follow-ups,' Dr Srinath said. Padma Shri Dr Rajendra A Badwe, chief executive of Tata Cancer Care Foundation and former Director of Tata Memorial Centre, has seen the full spectrum of caregiver experiences: 'Caregivers of cancer patients commonly face a range of challenges. Physically, they often experience fatigue and exhaustion from the demands of caregiving. Emotionally and psychologically, anxiety and depression are common, along with an inability to care for their own needs.' Yet he's also witnessed remarkable resilience. 'Some of them show remarkable courage to face the situation and garner strength to arrange everything so that no stone is unturned in treatment of their loved ones,' he told What makes the caregiver crisis particularly acute in India is the cultural context. For Ayushi Mathur, 37, who has been caring for her mother with metastatic breast cancer since 2018, the challenge is compounded by cultural expectations. 'Sacrifices and hard work are seen as your duty. You're just expected to do it.' Neha Cadabam, senior psychologist at Cadabams Hospitals, said this mindset leaves little space for caregivers to acknowledge their pain. 'Many internalise their distress, fearing it would be seen as selfish or inappropriate,' she said. The trauma can linger long after the crisis ends. 'Many caregivers experience flashbacks, anxiety, or a sense of purposelessness once their role ends,' Cadabam said. A caregiver's state of mind can shape the patient's outlook. 'When caregivers are calm and present, patients feel more secure. If they are distressed, patients can internalise that stress,' said Dr Srinath. Dr Badwe recalled one patient whose husband said, 'When so many good things happened to us, we never asked, 'Why me?'—so why ask now? We will face this together.' Despite the critical role caregivers play, India's healthcare system offers them minimal support. 'At present, India's healthcare system is still deeply focused on the patient, with very little formal support for the caregiver,' noted Dr Srinath. Mathur's experience, too, reflected this gap: 'Unfortunately, this is something that we haven't witnessed yet. While there have been silent acknowledgements of the emotional needs of a caregiver, however, there hasn't been any direct conversation or space given to discuss the emotional needs of caregivers.' Left to their own devices, caregivers develop whatever coping mechanisms they can. Sharma, dealing with the complex emotions of caring for someone with whom she had a 'difficult relationship,' sought therapy while in the US. 'I had a difficult relationship with my father, and when I was in the US, I took therapy to process how I was feeling about his deteriorating condition,' she said. 'To cope, I do meditation whenever I can. I also write and try my best to go to the gym. I also consume marijuana gummies from time to time when I feel a lot of stress,' Sharma said. Agrawal's struggle continues years later. 'That uncertainty, never knowing how he'd be the next day, or what news we'd get, weighed on me constantly. It was emotionally exhausting. I didn't know how to process what I was feeling at the time, and honestly, even today, I struggle. I find it hard to open up or feel emotionally comfortable around people,' she said. Caregivers often only process their trauma years later. Sharma fell into depression three years after her father's death. 'During the illness, you live in survival mode,' she said. Pillai said this is common: 'Even after recovery or loss, many live as though the next crisis is just around the corner.' Experts call for systemic reform. Dr Badwe recommended patient navigation services, distress assessment tools, and AI-enabled coping apps for caregivers. Pillai said, 'Hospitals must integrate routine mental health check-ins and provide on-site counsellors.' As India grapples with rising cancer rates—with over 1.4 million new cases diagnosed annually—the army of invisible caregivers continues to grow. These family members are sacrificing their careers, health, and happiness to fill the gaps in a healthcare system that hasn't yet learned to see them.
Hindustan Times
4 hours ago
- Hindustan Times
Elon Musk didn't like Silicon Valley, and neither did Mark Zuckerberg, says Kumail Nanjiani: ‘What the f**k was that?'
Pakistani-American actor and comedian Kumail Nanjiani has revealed that tech mogul Elon Musk was not a fan of the popular comedy show, Silicon Valley. Kumail Nanjiani recalled a conversation with Elon Musk, where the latter told Kumail, he was not a big fan of Silicon Valley Speaking on Mike Birbiglia's podcast Working It Out, the 47-year-old actor recalled how the Tesla chief had a problem with the very first episode of the HBO comedy. 'He didn't like the show,' Nanjiani said, explaining that Elon was 'upset' about the show's opening scene. The pilot begins with Kid Rock playing at a lavish tech party where the crowd is visibly bored, something Elon took issue with. According to Kumail, the billionaire brushed it off by saying the parties he attended were 'much cooler' than the ones depicted on screen. 'It was like, 'Yeah, man. You're one of the richest people in the world. We're, like, losers on the show. Of course your parties are better than my parties. What are you talking about?'' Kumail recalled. The Eternals actor also recounted another awkward moment involving Facebook founder Mark Zuckerberg. In 2016, Kumail and his Silicon Valley co-star Martin Starr were invited to present at the Breakthrough Awards, an event co-founded by Mark to celebrate the world's leading scientists. On stage, the pair decided to revive a notorious gag from the show's first season finale, where a character jokingly calculates how long it would take to give sexual favours to an entire conference room. They retooled the crude bit for the awards ceremony, but it backfired immediately. 'He was like, 'What the f**k was that?'' Kumail recalled of Mark's reaction. 'And truly in that moment he was right,' he added. Despite these encounters, Silicon Valley went on to become one of the most acclaimed comedies. Over its six-season run, the show earned critical praise and multiple Emmy nominations for its sharp satire of the tech industry and the culture surrounding it. While it found a devoted fanbase for exposing the absurdities of startup life, Kumail's anecdotes show that some of the world's most powerful tech leaders didn't always appreciate being in on the joke.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
These biomarkers may predict organ failure, death in chronic kidney disease
A new study highlights biomarkers that may predict chronic kidney disease progression, opening new possibilities for targeted care and personalised medicine New Delhi If you or someone close to you is living with chronic kidney disease (CKD), doctors may soon have new ways to predict who is most likely to face kidney failure or early death. Researchers in the UK have found that certain biomarkers can indicate whether CKD patients are at higher risk of kidney failure or death. These results, cited in the Journal of the American Society of Nephrology in the study 'Biomarkers of Kidney Failure and All-Cause Mortality in CKD', highlight the new possibilities of personalised treatment. The study was led by researchers at the University of Surrey as part of the National Unified Renal Translational Research Enterprise (NURTuRE) CKD study and funded by Kidney Research UK. It analysed data from 2,884 adults with CKD across 16 UK nephrology centres. What is chronic kidney disease and why is it dangerous? According to Cleveland Clinic, an American nonprofit academic medical center, chronic kidney disease is a long-term condition where the kidneys slowly lose their ability to filter waste and excess fluids from the blood. It affects millions worldwide and often leads to serious complications like kidney failure, heart disease, and even early death. What did the study find? The researchers studied 21 biomarkers linked to kidney damage, fibrosis, inflammation, and cardiovascular stress. Out of these, some combinations stood out as strong predictors: For kidney failure: soluble TNF receptor 1 (sTNFR1), soluble CD40 (sCD40), and urinary collagen type 1 a1 chain (UCOL1A1). For all-cause mortality: high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), and soluble urokinase plasminogen activator receptor (suPAR). These biomarkers reflect different disease mechanisms like inflammation, cardiovascular strain, and tissue damage, helping paint a fuller picture of CKD progression. Dr Tony Onoja, lead author and research fellow at the University of Surrey, explained in a statement published on the university website, "Our research shows that these biomarker models offer predictive results comparable to established methods, but more importantly, they help us understand how the disease progresses. This could open the door to personalised treatments in the future." Professor Nophar Geifman, senior author of the study, added, "Specific biomarkers can give a more nuanced understanding of a patient's disease progression and mortality risk. Further research is needed to explore how these markers respond to treatments and how they can be integrated into clinical care." How can these biomarkers change future CKD treatments? According to the researchers, by identifying patients most at risk of kidney failure or early death, doctors may: Monitor disease progression more closely Develop personalised treatment strategies Test new targeted therapies that address inflammation, fibrosis, or cardiovascular stress Although more clinical validation is needed, these findings point towards a future where CKD management is far more personalised than it is today.
